FDA Approves Psilocybin for Treatment-Resistant Depression (TRD)
The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.
The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.
Researchers find that psilocybin changes blood flow, communication pathways, and activity in the brain, enabling "a state of unconstrained cognition."
Researchers find the psychosis produced from psilocybin in humans is due to activation of serotonin 2A receptors.
Alexander and Ann Shulgin publish "TiHKAL: The Continuation."
Alexander and Ann Shulgin publish "PiHKAL: A Chemical Love Story."
The Comprehensive Drug Abuse Prevention and Control Act is passed by the US Congress and psilocybin, LSD, and other hallucinogens are placed on Schedule I.
Timothy Leary first ingests psilocybin-containing mushrooms in Cuernavaca, Mexico.
Albert Hofmann isolates psilocybin and psilocin from mushrooms.
LIFE magazine publishes an article by R. Gordon Wasson called "Seeking the Magic Mushroom."
Albert Hofmann synthesizes LSD-25 for the first time while working at Sandoz Laboratories in Switzerland.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.